ATE326014T1 - Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma - Google Patents

Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma

Info

Publication number
ATE326014T1
ATE326014T1 AT99962732T AT99962732T ATE326014T1 AT E326014 T1 ATE326014 T1 AT E326014T1 AT 99962732 T AT99962732 T AT 99962732T AT 99962732 T AT99962732 T AT 99962732T AT E326014 T1 ATE326014 T1 AT E326014T1
Authority
AT
Austria
Prior art keywords
ldl
lipoprotein
vldl
compound
plasma cholesterol
Prior art date
Application number
AT99962732T
Other languages
English (en)
Inventor
Russell M Medford
Uday Saxena
Original Assignee
Atherogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atherogenics Inc filed Critical Atherogenics Inc
Application granted granted Critical
Publication of ATE326014T1 publication Critical patent/ATE326014T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT99962732T 1998-11-09 1999-11-09 Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma ATE326014T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10764498P 1998-11-09 1998-11-09

Publications (1)

Publication Number Publication Date
ATE326014T1 true ATE326014T1 (de) 2006-06-15

Family

ID=22317677

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99962732T ATE326014T1 (de) 1998-11-09 1999-11-09 Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma

Country Status (10)

Country Link
EP (1) EP1137948B1 (de)
JP (1) JP2002529740A (de)
CN (1) CN1332849A (de)
AT (1) ATE326014T1 (de)
AU (1) AU1911200A (de)
CA (1) CA2350316A1 (de)
DE (1) DE69931279T2 (de)
IL (2) IL143057A0 (de)
MX (1) MXPA01004683A (de)
WO (1) WO2000028332A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1275596C (zh) 1997-05-14 2006-09-20 阿特罗吉尼克斯公司 普罗布考单酯在制备用于治疗心血管疾病和炎性疾病的药物中的应用
US6670398B2 (en) 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US6852878B2 (en) 1998-05-14 2005-02-08 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of VCAM-1
CO5170498A1 (es) * 1999-05-28 2002-06-27 Abbott Lab Biaril sulfonamidas son utiles como inhibidores de proliferacion celular
KR100511732B1 (ko) 1999-10-04 2005-09-01 닛뽕소다 가부시키가이샤 페놀성 화합물 및 그를 사용한 기록 재료
CA2403823A1 (en) * 2000-03-21 2001-09-27 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of vcam-1
US6881860B2 (en) 2000-04-11 2005-04-19 Atherogenics, Inc. Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality
AU2002308295B2 (en) 2001-03-12 2007-08-23 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
ITMI20020597A1 (it) * 2002-03-22 2003-09-22 Nicox Sa Derivati del probucolo
US20070260087A1 (en) 2004-04-20 2007-11-08 Atherogenics, Inc. Process of Preparing Esters and Ethers of Probucol and Derivatives Thereof
EP2139320A4 (de) 2007-03-26 2010-09-08 Salutria Pharmaceuticals Llc Verfahren und zusammensetzungen von probucol-derivaten für die behandlung von diabetes
US8048880B2 (en) 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
JP2012530900A (ja) * 2009-06-17 2012-12-06 メイン スタンダーズ カンパニー リミテッド ライアビリティ カンパニー リポタンパク質特異的アポリポタンパク質を測定する方法
CN114085283A (zh) * 2015-05-19 2022-02-25 拉·约拉过敏反应及免疫医学研究所 调节炎症应答及治疗不良心血管事件、病和粥样硬化的人apob100表位、方法和用途
WO2018045015A1 (en) * 2016-09-01 2018-03-08 Kevin Jon Williams Methods and kits for reducing the susceptibility of lipoprotein particles to atherogenic aggregation induced by arterial-wall enzymes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869534A (en) * 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US5155250A (en) * 1990-07-05 1992-10-13 Merrell Dow Pharmaceuticals Inc. 2,6-di-alkyl-4-silyl-phenols as antiatheroscerotic agents
DE69434720T2 (de) * 1993-12-10 2007-05-16 Aventis Inc. Verwendung von 2,6-Dialkyl-4-Silyl-Phenol Derivaten zur Behandlung von Xanthom
US5608095A (en) * 1996-04-30 1997-03-04 Hoechst Marion Roussel, Inc. Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents
CH691957A5 (de) * 1996-09-03 2001-12-14 Urs Tschudin Schleifmaschine.

Also Published As

Publication number Publication date
DE69931279D1 (de) 2006-06-14
WO2000028332A9 (en) 2000-09-28
IL143057A0 (en) 2002-04-21
MXPA01004683A (es) 2002-09-18
EP1137948B1 (de) 2006-05-10
JP2002529740A (ja) 2002-09-10
CA2350316A1 (en) 2000-05-18
AU1911200A (en) 2000-05-29
EP1137948A1 (de) 2001-10-04
DE69931279T2 (de) 2007-04-12
CN1332849A (zh) 2002-01-23
IL143057A (en) 2010-04-15
WO2000028332A1 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
ATE326014T1 (de) Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma
Roberts et al. A cell-based model of thrombin generation
Oka et al. Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive
Kane et al. Prebeta-1 HDL and coronary heart disease
Roy et al. Mutational and biochemical analysis of plasma membrane targeting mediated by the farnesylated, polybasic carboxy terminus of K-ras4B
Marais et al. Dysbetalipoproteinaemia: a mixed hyperlipidaemia of remnant lipoproteins due to mutations in apolipoprotein E
ZA200107598B (en) Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein Al, very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol.
Connelly et al. Analysis of chimeric receptors shows that multiple distinct functional activities of scavenger receptor, class B, type I (SR-BI), are localized to the extracellular receptor domain
MY121405A (en) 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines
MY130670A (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
MY121838A (en) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
ATE204330T1 (de) Verfahren zur bestimmung von cholesterin in high- density lipoproteinen
AU2864195A (en) Class bi and ci scavenger receptors
De Cristofaro et al. The Asp272–Glu282 Region of Platelet Glycoprotein Ibα Interacts with the Heparin-binding Site of α-Thrombin and Protects the Enzyme from the Heparin-catalyzed Inhibition by Antithrombin III
Arosio et al. Mutation of W215 compromises thrombin cleavage of fibrinogen, but not of PAR-1 or protein C
TW200510452A (en) Compositions and methods for treating atherosclerosis
WO2004005481A3 (en) Methods for identifying modulators of mda-7 mediated apoptosis
Arocas et al. The role of Arg46 and Arg47 of antithrombin in heparin binding
Daum et al. Multiple dysfunctions of two apolipoprotein AI variants, apoA-I (R160L) Oslo and apoA-I (P165R), that are associated with hypoalphalipoproteinemia in heterozygous carriers
IL160533A0 (en) Methods of screening molecules that are used to prevent cardiovascular diseases
Klein et al. Phosphatidylethanolamine participates in the stimulation of the contact system of coagulation by very-low-density lipoproteins
NO20002408L (no) 5-HT1F antagonister
DE69716057D1 (de) Verfahren und zusammensetzungen zum nachweis von spleiss-mutationen in dihydropyremudine dehydrogenase
Minnich et al. Identification and characterization of a novel apolipoprotein E variant, apolipoprotein E3'(Arg136–> His): association with mild dyslipidemia and double pre-beta very low density lipoproteins
Boffelli et al. The uptake of cholesterol at the small‐intestinal brush border membrane is inhibited by apolipoproteins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties